BMJ Open

Clinical profile, risk factors and outcomes of pediatric COVID-19: a retrospective cohort multicentre study in Saudi Arabia

Waleed H Albuali,1,2 Amal A AlGhamdi,3 Shaikha J Aldossary,1,2 Saleh A AlHarbi,4,5 Sami I Al Majed,6 Ahmed Alenizi,7 Mohammad H Al-Qahtani,1,8 Amer A Lardhi,1,2 Shams A Al-Turki,1,2 Abdulaziz S AlSanea,1,2 Dalal K Bubshait,1,2 Sumayyah A Kobeisy,3 Noor H Herzallah,6 Wejdan A Alqarni,3 Abeer H AlHarbi,7 Hamad W Albuali,2 Bader J Aldossary,2 Faisal O AlQurashi,1,2 Abdullah A Yousei1,2

ABSTRACT

Objective To describe the risk factors, clinical profile and outcomes of COVID-19 in the paediatric population.

Design Multicentre, retrospective observational study.

Setting Four tertiary hospitals in Saudi Arabia.

Patients We recruited 390 paediatric patients aged 0–18 years who presented from March to December 2020 and tested positive for COVID-19 on PCR.

Main outcome measures We retrospectively analysed medical records for sociodemographics, health indicators, clinical presentations, laboratory findings, clinical complications, and outcomes.

Results The mean participant age was 5.66±4.90 years, and the mean hospital stay was 2.17±3.48 days. Forty patients, mostly school-aged children (16, 40.00%; p=0.005) and children with comorbidities (25, 62.50%; p<0.001), received more than just supportive care. Complications were seen in 15 (3.9%) patients, bacterial infection being the most common (6, 40.00%). Patients presented with dyspnoea (OR 6.89; 95% CI 2.89 to 20.72), abnormal chest radiographs (OR 6.11; 95% CI 2.91 to 28.06) and lethargy (OR 9.04; 95% CI 2.91 to 28.06) and elevated ferritin and D-dimer (OR 48.40; 95% CI 1.02 to 12.30). The complication and intensive care unit (ICU) admission rates are much lower for children than for adults.

Conclusions COVID-19 complications were limited among our patients. However, dyspnoea, abnormal chest radiographs, lethargy and elevated ferritin and D-dimer levels were associated with higher odds of developing complications. Dyspnoea, leucocytosis, comorbidities and abnormal chest radiographs at presentation increased the risk of ICU admission.

INTRODUCTION

By March 2020, COVID-19 was declared a pandemic by WHO.1 This pandemic inflicted a major burden on the healthcare system, especially the intensive care units (ICUs). Initial reports on COVID-19 concentrated primarily on the adult population and included the clinical presentation and management recommendations.2 This may have been because the pneumonia-related symptoms are more common in adults than in children.3 The first paediatric COVID-19
case was discovered in Shenzhen, China, on 20 January 2020. However, after COVID-19 screening campaigns were initiated in multiple regions worldwide, more paediatric cases were discovered, and the concept of silent carriers or patients with mild disease symptoms became known in this population.

The incidence of paediatric COVID-19 (aged ≤18 years) is reportedly 0.8%–2.0% of all cases. A multicentre cohort study involving 25 European countries concluded that COVID-19 could be manifested throughout the paediatric age scale. In that study, Götzinger et al found that 7% of 582 paediatric COVID-19 cases were under 1 month old, 22% were 1–12 months old, 10% were 1–2 years old, 11% were 2–5 years old, 16% were 5–10 years old, and 34% were older than 10 years. The incidence of paediatric COVID-19 in Saudi Arabia paralleled the figures found in other international reports, with a local incidence of 4%. In one local study, most paediatric patients presented with mild symptoms.

Apart from the classic symptoms of COVID-19, which include fever, cough, and shortness of breath, paediatric patients were exclusively linked to the occurrence of a unique medical phenomenon termed ‘multisystem inflammatory syndrome in children’ (MIS-C). MIS-C was reported in several international studies to affect critically ill children infected with SARS-CoV-2. MIS-C was handled as a distinct entity because of its wide range of severity levels and multisystem manifestations, including gastrointestinal symptoms, rash, heart lesions and shock. An overlap between MIS-C features and those of Kawasaki disease has been reported by several authors, although the latter usually occurs in younger children than COVID-19.

Although there are numerous reports about the epidemiology, clinical presentation, laboratory and radiological findings, and outcomes of COVID-19, most are primarily based on adult populations, with variable focus on the paediatric age group. Paediatric reports on COVID-19 among Saudi population were limited by a cross-sectional design accompanied by a single-centre setting or a small sample size. Accordingly, their findings cannot be generalised to the paediatric COVID-19 patient population.

This study aimed to identify the risk factors, initial clinical presentation and laboratory findings, and outcomes in paediatric COVID-19 patients presented to four medical centres in different regions of Saudi Arabia.

METHODS

This was a multicentre, retrospective observational study conducted in four tertiary hospitals in the Eastern, Middle and Western provinces of Saudi Arabia. The participating institutions were King Fahd Hospital of the University, Alkhobar; Johns Hopkins Aramco Healthcare, Dhahran; King Saud Medical City, Riyadh; and Dr. Soliman Fakeeh Hospital, Jeddah. Collectively, their paediatric ward capacity is 325 beds, and the paediatric ICU (PICU) capacity is 56 beds. All four hospitals were designated as COVID-19 centres at the beginning or during the study period. The study included all paediatric patients (age ≤18 years) who presented to these hospitals from May to August 2020 and were SARS-CoV-2 PCR-positive following the nationally adopted screening criteria. Patients with incomplete or missing data were excluded from the study.

The retrieved data were as follows: age (infant, <1 year; toddler, 1–2 years; preschool, 3–5 years; school age, 6–11 years; adolescent, 12–18 years); sex; region (Western, Eastern and Central); admission status (admitted or not admitted); route of recruitment (emergency room (ER), paediatric ward, PICU); history of contact with COVID-19-confirmed case (yes or no); presence of comorbidities (yes or no) such as cardiac, respiratory, neurological, endocrinological, haematological, gastroenterological and other diseases; month of admission; duration of admission; presence of complications (yes or no) and the complication type; type of treatment received (supportive or other interventions, including medication and ventilation); presence of symptoms at admission (yes or no), including fever, cough, sore throat, headache, dyspnoea, rash, myalgia, rhinorrhoea and diarrhoea; laboratory blood test results at the time of presentation (normal, increased or decreased), including white cell count (WCC) and differential counts, platelet count, C reactive protein, erythrocyte sedimentation rate, ferritin, bilirubin, aspartate transaminase, alanine transaminase, creatine kinase (CPK), lactate dehydrogenase (LDH), albumin, creatinine and D-dimer; chest radiography findings (normal, unilateral consolidation, bilateral consolidations or ground glass appearance); and outcome (discharge, death).

All analyses were performed using Stata V.16 (StataCorp). We used the t-test, the χ² test or Fisher’s exact test as appropriate for comparisons of different age groups and other study variables. Additionally, unadjusted and adjusted (for age and sex) logistic regression models estimated the odds of developing abnormal blood results and complications among study participants. Continuous values are presented as mean±SD. Categorical variables are presented as number and percentage.

Patient and public involvement

No patient involved.

RESULTS

Participants

This study included 390 patients. As seen in table 1, most participants were from the Western region (247, 63.3%), female (203, 52.1%) and infants (115, 29.5%). The participants’ age was 5.66±4.90 years (0.5–18.0 years), weight was 20.46±13.17 kg (2.0–50.0 kg), and hospital stay was 2.17±3.48 days (0–18 days). Fifteen patients (3.9%) developed complications, with bacterial infection (6, 40.0%),
acute respiratory distress syndrome (ARDS; 2, 13.33%) and shock (2, 13.33%) being most common.

**Symptoms at presentation**

In regard to infant participants, 61 infants were 6 months old or younger (15.64%); 32 of these (52.46%) were male. Many of these infants had COVID-19 symptoms that required admission (29, 47.54%) and 41 (67.21%) had a history of being in contact with a COVID-19-positive case. Furthermore, 50 (81.97%) had no comorbid conditions. Of the 11 infants (18.03%) with a comorbid disease in this young infant group, three had a cardiac disease and three had a neurological disease. Thirty-nine (63.93%) had fever, 22 (36.07%) had rhinologic symptoms, 21 (34.43%) had cough, 12 (19.67%) had diarrhoea and 6 (9.84%) had lethargy. None showed a rash at presentation. In regard to other participants, fever was the most common symptom at presentation 269 (68.97%) especially among older children. In addition, cough was statistically significantly more common among adolescents 36 (56.25%) as well as dyspnoea 19 (26.69%). Symptoms of

### Table 1: Study participants sociodemographic features

| Age group            | Asymptomatic* n (%) | Symptomatic n (%) | Total n (%) | χ² | df | P value |
|----------------------|---------------------|-------------------|-------------|----|----|---------|
| Infant (<1 year)     | 74 (64.35)          | 41 (35.65)        | 115 (29.5)  | 0  | 1  | 0.009†  |
| Toddler (1–2 years)  | 36 (90.00)          | 4 (10.00)         | 40 (10.3)   |    |    |         |
| Preschool (3–5 years)| 46 (76.67)          | 14 (23.33)        | 60 (15.4)   |    |    |         |
| School age (6–11 years) | 89 (80.18)     | 22 (19.82)        | 111 (28.5)  |    |    |         |
| Adolescent (≥12 years)| 49 (76.56)       | 15 (23.44)        | 64 (16.4)   |    |    |         |
| Sex                  |                     |                   |             |    |    |         |
| Male                 | 133 (71.12)         | 54 (28.88)        | 187 (48.0)  | 3.52|1  | 0.06    |
| Female               | 161 (79.3)          | 42 (20.7)         | 203 (52.1)  |    |    |         |
| Region               |                     |                   |             |    |    |         |
| Western              | 212 (85.8)          | 35 (14.2)         | 247 (63.3)  | 89.41|2  | <0.001  |
| Eastern              | 65 (79.27)          | 17 (20.13)        | 82 (21.0)   |    |    |         |
| Central              | 17 (27.87)          | 44 (72.13)        | 61 (15.6)   |    |    |         |
| Admission status     |                     |                   |             |    |    |         |
| Not admitted         | 227 (100.0)         | 0 (0.0)           | 227 (58.2)  |    |    | <0.001† |
| Admitted             | 67 (41.10)          | 96 (58.90)        | 163 (41.8)  |    |    |         |
| Rout                 |                     |                   |             |    |    |         |
| Emergency room       | 227 (99.6)          | 1 (0.4)           | 228 (58.5)  |    |    | <0.001† |
| Paediatric ward      | 64 (42.38)          | 8 (7.62)          | 151 (38.7)  |    |    |         |
| PICU                 | 3 (27.27)           | 8 (72.73)         | 11 (2.8)    |    |    |         |
| Contact with COVID-19-positive cases | | | | | | |
| No                   | 92 (69.70)          | 40 (30.30)        | 132 (33.9)  | 3.48|1  | 0.06    |
| Yes                  | 202 (78.3)          | 56 (21.7)         | 258 (66.2)  |    |    |         |
| Comorbidity          |                     |                   |             |    |    |         |
| No                   | 248 (76.8)          | 75 (23.2)         | 323 (82.8)  | 1.97|1  | 0.16    |
| Yes                  | 46 (68.66)          | 21 (31.34)        | 67 (17.2)   |    |    |         |
| Season of admission  |                     |                   |             |    |    |         |
| Spring (March–May)   | 37 (57.81)          | 27 (42.19)        | 64 (16.4)   |    |    | 0.001†  |
| Summer (June–August) | 248 (79.2)         | 65 (20.8)         | 313 (80.3)  |    |    |         |
| Autumn (September–November) | 9 (69.23) | 4 (30.77)         | 13 (3.3)    |    |    |         |

*Asymptomatic or with mild symptoms at admission
†Indicates that the p value was calculated by Fisher’s exact test
PICU, paediatric intensive care unit.

*Albuali WH, et al. BMJ Open 2022;12:e053722. doi:10.1136/bmjopen-2021-053722*
COVID-19 at presentation according to paediatric age groups are listed in Table 2.

**Labratory test results at presentation**
Table 3 summarises the investigation results by age groups. Among the 6 months old or younger infants, abnormal D-dimer was found in four (6.56%), high ferritin in three (4.92%), elevated LDH in seven (11.48%), and abnormal lymphocyte count in 13 (21.21%); lymphocyte counts were increased and decreased in six (84.78%) and seven (15.22%) cases, respectively.

**Treatments and interventions of COVID-19**
As seen in Table 4, most patients received supportive treatment. However, 14 received hydroxychloroquine, five received dexamethasone, and 20 received a combination of treatments. Most of the 40 children requiring more than supportive care were school-age children (16, 40%; Fisher’s exact test, p=0.005), and children with pre-existing comorbidities (25, 62.50%; \( \chi^2(1)=62.50, p<0.001 \)). Complications were seen in 15 participants (3.85%) and they mainly were due to secondary infection (640%). Only two patients died during the study period. One was a 1-year-old girl with a neurological disease who developed ARDS, and the other was a 10-year-old boy with no comorbidities who developed shock.

Most patients admitted to the PICU were preschool children (7/11, 63.64%; \( \chi^2(5)=13.23, p=0.02 \)). The mean PICU stay was 8±3.44 days (3–16 days) and most patients were discharged without complications (8/11, 72.73%; \( \chi^2(1)=16.79, p<0.001 \)). Of the 11 PICU patients, 1 received supportive care, one received dexamethasone,
5 received hydroxychloroquine and 4 received a combination of dexamethasone and hydroxychloroquine.

**Risk estimation of developing poor COVID-19 outcomes**

After age adjustment in the logistic regression models, the odds of having elevated LDH were lower in female patients (OR 0.43; 95% CI 0.20 to 0.91) and patients with higher body weight (OR 0.90; 95% CI 0.84 to 0.97), while they were higher in patients with preexisting comorbidities (OR 5.63; 95% CI 2.67 to 11.85), increased lymphocyte count (OR 3.90; 95% CI 1.50 to 10.13) and increased platelet count (OR 5.04; 95% CI 1.80 to 14.08).

No association was found between increased LDH and the presence of various symptoms at presentation.

The odds of having elevated lymphocyte count were lower in patients with fever at presentation (OR 0.23; 95% CI 0.09 to 0.55) and higher in patients with

---

**Table 3  Central tendency measures (mean and SD) of laboratory investigations**

| Measured laboratory tests | Paediatric age groups* | Infant n=115 | Toddler n=40 | Preschool n=60 | School age n=111 | Adolescent n=64 |
|---------------------------|------------------------|-------------|-------------|---------------|----------------|---------------|
| Lab test                  | Status                 | Number      | Unit        | M  | SD  | M  | SD  | M  | SD  | M  | SD  |
| WCC (n=206)               | Normal                 | 154         | (x10^9/L)   | 10.66 | 5.20 | 10.49 | 4.71 | 8.71 | 5.54 | 9.26 | 5.78 | 7.28 | 4.54 |
|                           | Increased              | 26          |             |        |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 26          |             |        |      |      |      |      |      |      |      |      |      |
| Neutrophil (n=204)        | Normal                 | 143         | (x10^9/L)   | 3.13  | 2.93 | 4.02  | 3.21 | 4.01  | 3.76 | 5.01  | 4.63 | 4.01  | 3.76 |
|                           | Increased              | 20          |             |        |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 41          |             |        |      |      |      |      |      |      |      |      |      |
| Lymphocyte (n=205)        | Normal                 | 145         | (x10^9/L)   | 5.21  | 3.04 | 5.49  | 2.69 | 3.64  | 3.44 | 2.28  | 1.51 | 4.15  | 13.89 |
|                           | Increased              | 25          |             |        |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 35          |             |        |      |      |      |      |      |      |      |      |      |
| Eosinophil (n=197)        | Normal                 | 147         | (x10^9/L)   | 0.32  | 0.44 | 0.17  | 0.33 | 0.06  | 0.07 | 0.30  | 0.81 | 0.13  | 0.92 |
|                           | Increased              | 5           |             |        |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 45          |             |        |      |      |      |      |      |      |      |      |      |
| Platelet (n=206)          | Normal                 | 176         | (x10^9/L)   | 377.89 | 160.92 | 306.39 | 120.45 | 275.17 | 77.79 | 286.54 | 129.91 | 251.89 | 87.89 |
|                           | Increased              | 21          |             |        |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 9           |             |        |      |      |      |      |      |      |      |      |      |
| ESR (n=12)                | Normal                 | 5           | (mm/hr)     | 28.00 | 28.84 | 10.00 | 0.000 | 73.33 | 46.46 | 16.33 | 10.25 | 46    | 56.51 |
|                           | Increased              | 7           |             |        |      |      |      |      |      |      |      |      |      |      |
| Ferritin (n=50)           | Normal                 | 30          | (ng/mL)     | 214.88 | 193.69 | 169.83 | 215.45 | 40.57 | 28.00 | 612.15 | 882.75 | 511.69 | 1656.63 |
|                           | Increased              | 18          |             |        |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 2           |             |        |      |      |      |      |      |      |      |      |      |
| Bilirubin (n=108)         | Normal                 | 86          | (mg/dL)     | 34.60 | 57.74 | 21.06 | 45.33 | 14.42 | 22.46 | 9.80  | 18.64 | 11.93 | 15.50 |
|                           | Increased              | 21          |             |        |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 1           |             |        |      |      |      |      |      |      |      |      |      |
| AST (n=111)               | Normal                 | 93          | (U/L)       | 41.53 | 29.66 | 41.14 | 16.19 | 50.18 | 31.56 | 49.33 | 83.24 | 27.03 | 16.59 |
|                           | Increased              | 18          |             |        |      |      |      |      |      |      |      |      |      |      |
| ALT (n=119)               | Normal                 | 111         | (U/L)       | 25.25 | 25.64 | 20.37 | 6.60  | 21.66 | 24.50 | 19.19 | 17.44 | 14.38 | 14.49 |
|                           | Increased              | 5           |             |        |      |      |      |      |      |      |      |      |      |      |
| LDH (n=66)                | Normal                 | 32          | (U/L)       | 329.33 | 33.45 | 453.33 | 263.52 | 242.50 | 108.70 | 548.80 | 601.69 | 223.07 | 103.39 |
|                           | Increased              | 33          |             |        |      |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 1           |             |        |      |      |      |      |      |      |      |      |      |      |
| Albumin (n=108)           | Normal                 | 100         | (g/L)       | 30.87 | 14.41 | 38.09 | 12.36 | 30.13 | 18.00 | 29.95 | 18.00 | 23.59 | 18.99 |
|                           | Decreased              | 8           |             |        |      |      |      |      |      |      |      |      |      |      |
| Creatines (n=154)         | Normal                 | 82          | (mg/mL)     | 0.42  | 0.55 | 0.36  | 0.62 | 1.99  | 7.03 | 1.00  | 1.85 | 0.62  | 0.17 |
|                           | Increased              | 6           |             |        |      |      |      |      |      |      |      |      |      |      |
|                           | Decreased              | 66          |             |        |      |      |      |      |      |      |      |      |      |      |
| D-dimer (n=40)            | Normal                 | 14          | (µg/mL)     | 1.32  | 0.14 | 2.31  | 1.49 | 1.68  | 1.84 | 2.63  | 1.79 | 0.94  | 1.10 |
|                           | Increased              | 26          |             |        |      |      |      |      |      |      |      |      |      |      |

*Infant, <1 year; toddler, 1–2 years; preschool, 3–5 years; school age, 6–11 years; adolescent, 12–18 years
ALT, alanine transaminase; AST, aspartate transaminase; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; WCC, white cell count.
pre-existing comorbidities (OR 3.54; 95% CI 1.47 to 8.51). The odds of developing higher ferritin were lower in patients with higher body weight (OR 0.82; 95% CI 0.73 to 0.91), dyspnoea (OR 3.08; 95% CI 1.06 to 8.98) and pre-existing comorbidities (OR 15.84; 95% CI 5.38 to 46.62).

The odds of having elevated D-dimer were lower in patients with higher body weight (OR 0.85; 95% CI 0.77 to 0.92) and higher in the presence of cough (OR 2.59; 95% CI 1.13 to 5.91), dyspnoea (OR 4.29; 95% CI 1.77 to 10.42), rash (OR 11.06; 95% CI 2.51 to 52.74), fatigue and myalgia (OR 6.96; 95% CI 2.76 to 17.54) and pre-existing comorbidities (OR 12.29; 95% CI 5.14 to 29.36).

The development of complications increased the odds of interventional treatment (OR 17.68; 95% CI 5.14 to 53.71). The odds of developing complications were higher in patients presenting with dyspnoea (OR 4.66; 95% CI 1.24 to 17.50) and elevated WCC count (adjusted OR 3.54; 95% CI 1.02 to 12.30) for further results please refer to tables 5 and 6.

**DISCUSSION**

On 2 March 2020, the first confirmed case of paediatric COVID-19 was discovered in Saudi Arabia. After reviewing the literature, this work represents the largest multicentre observational study of paediatric COVID-19, involving three major regions in the kingdom and a significant cohort size, comparable to international reports on the topic. In our cohort, males and females were equally affected. We found that 29.49% participants were infants (<1 year), 10.3% were 1–2 years old, 15.4% were 3–5 years old, 28.5% were 6–11 years old and 16.4% were over 12 years old. This age structure finding is somewhat comparable to other international reports, except for the second most affected age group. It was children aged 6–11 years in our study and adolescents (>11 years) in other reports. This could be because school-aged children comprised almost one-third of our study population. The observation of infants being more affected

| Table 4 | The distribution of COVID-19 outcomes in relation to presence of symptoms at admission |
|---------|---------------------------------|---|---|---|---|---|---|---|
| Outcome                          | Asymptomatic | Symptomatic | Total | X² | df | P value |
|                                  | N=294 | 75.38% | N=96 | 24.62% | N=390 | 100% |
| Complications                     |       |       |       |       |       |       |
| No                                | 291 | 98.97% | 84 | 87.50% | 375 | 96.15% | 25.79 | 1 | <0.001 |
| Yes                               | 3  | 1.02% | 12 | 12.50% | 15 | 3.84% |
| ARDS                             | 0  |          | 2  |          |
| Acute cardiac injury              | 0  |          | 2  |          |
| Acute kidney injury               | 0  |          | 1  |          |
| Shock                            | 1  |          | 1  |          |
| Secondary infections              | 1  |          | 5  |          |
| Other                            | 1  |          | 2  |          | 14.12 | 1 | <0.001 |
| PICU admission                    |       |       |       |       |       |       |
| No                                | 291 | 98.97% | 88 | 91.66% | 379 | 97.17% |
| Yes                               | 3  | 1.02% | 8  | 8.33% | 11 | 2.82% |
| Treatment received                |       |       |       |       |       |       |
| Supportive                       | 269 | 91.49% | 81 | 84.37% | 350 | 89.74% | 3.99 | 1 | 0.046 |
| Other interventions              | 25  | 8.50%  | 15 | 15.62% | 40 | 10.25% |
| Ventilator                       | 0  |          | 1  |          |
| Dexamethasone                     | 3  |          | 2  |          |
| Hydroxychloroquine                | 5  |          | 9  |          |
| Combination treatment            | 17  |          | 3  |          |
| Mortality                         |       |       |       |       |       |       |
| Discharged                       | 293 | 99.65% | 95  | 98.95% | 388 | 99.48% | 0.432* |
| Death                             | 1  | 0.34%  | 1  | 1.04%  | 2  | 0.51% |

*P value comes from Fisher’s exact test. ARDS, acute respiratory distress syndrome; PICU, paediatric intensive care unit.
by the disease could be due to their relatively immature immune system.24

Most of our patients were asymptomatic or had mild symptoms, and only around one-third of them required hospital admissions. This observation is similar to previous reports on paediatric COVID-19.25 26 Only 2.8% of our patients required intensive care admission. This observation was found in various international studies and confirmed that the paediatric age group had a milder degree of COVID-19 than adults.12 20 26 In one local multicentre study of 88 COVID-19 patients, the rate of PICU admission was higher than ours (8%).27 This could be because our national COVID-19 guidelines had been revised in May 2020, adopting a lower threshold for defining suspected COVID-19 cases qualifying for PCR screening. This change allowed the discovery of asymptomatic paediatric patients and those with mild symptoms.22 Compared with international reports, the percentage of our asymptomatic patients and those with mild symptoms (75.4%) was slightly lower than in two previous major metaanalyses (98% and 96%).28 29 This could be because our indicators for disease severity were based on multiple factors and not merely on the severity of symptoms. These included fever measured or subjectively reported by history, respiratory symptoms of any severity, and mild symptoms of the disease with a history of contact with a confirmed COVID-19 case.

We report a mean hospital stay of 2.17 days (1–18 days), the lowest in all local and international studies to date. A local study by Kari et al reported a hospital stay of 5.9 days.20 In the UK, the average stay was 3 days.27 A case series by Xia et al reported an average hospital stay of 12.9 days.30 This difference could be due to our nationally adopted protocol involving discontinuation of isolation of confirmed mild COVID-19 cases, characterised by a passage of 10 days from the start of the symptoms, resolution of fever for at least 3 days without antipyretic drugs, and alleviation of other symptoms.22 Fever was the most observed symptom (69%), followed by cough (34.3%) and rhinorrhoea (29.2%). In comparison, previous reports noted fever as the most observed symptom, ranging between 41% and 59% cases, while cough was the second most prominent symptom (37%–46%).26–34 Only 3.85% patients in our cohort developed complications, with the most common being bacterial infection (40.0%), ARDS (13.3%) and shock (13.3%). Furthermore,

Table 5 Summary of logistic regression models that estimate the risk of developing poor prognostic laboratory findings of COVID-19

| Age | Elevated ferritin | Elevated D dimer | Elevated LDH | Lymphocytopenia | Elevated creatinine | Decreased platelet |
|-----|------------------|------------------|--------------|----------------|---------------------|-------------------|
| ≤5 years | Ref. | 4.16 | 0.12 | 0.61 | 1.79 | 0.84 | 1.76 | 0.76 | 0.70 |
| 6–11 years | 2.07 | 1.39 | 0.81 | 1.90 | 1.10 | 1.00 | 0.61 | 0.17 | 0.42 |
| ≥12 years | 2.07 | 1.39 | 0.81 | 1.90 | 1.10 | 1.00 | 0.61 | 0.17 | 0.42 |

Gender

| Male | Ref. | 0.69 | 0.26 | 0.87 | 0.39 | 0.43 | 0.20 | 0.91 | 0.08 |
| Female | 0.82 | 0.73 | 0.91 | 0.85 | 0.77 | 0.92 | 0.90 | 0.84 | 0.97 |

Weight (kg)

| Yes | 15.84 | 5.38 | 46.62 | 12.29 | 5.14 | 29.36 | 5.63 | 2.67 | 11.85 | 0.49 | 0.19 | 1.25 | 1.28 | 0.31 | 5.31 |
| No | 1.06 | 8.98 | 4.29 | 2.79 | 1.01 | 7.75 | 1.79 | 0.77 | 4.18 | 1.78 | 0.76 | 4.16 | 1.21 | 1.10 | 8.58 | 1.04 | 2.22 | 4.94 |

Comorbidities

| Yes | 3.08 | 1.06 | 8.98 | 4.29 | 2.79 | 1.01 | 7.75 | 1.79 | 0.77 | 4.18 | 1.78 | 0.76 | 4.16 | 1.21 | 1.10 | 8.58 | 1.04 | 2.22 | 4.94 |

Chest X-ray

| Yes | 1.77 | 0.67 | 4.70 | 2.59 | 1.13 | 5.91 | 1.96 | 0.94 | 4.08 | 1.04 | 0.48 | 2.24 | 0.35 | 0.04 | 3.14 | 1.01 | 0.24 | 4.23 |

Fever

| Yes | 0.63 | 0.24 | 1.70 | 1.43 | 0.56 | 3.69 | 0.67 | 0.32 | 1.40 | 2.96 | 1.08 | 8.10 | 0.15 | 0.03 | 0.89 | 1.64 | 0.33 | 8.24 |

Table 5 Summary of logistic regression models that estimate the risk of developing poor prognostic laboratory findings of COVID-19

Elevated ferritin Elevated D dimer Elevated LDH Lymphocytopenia Elevated creatinine Decreased platelet

OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI

Age

| ≤5 years | Ref. | 4.16 | 0.12 | 0.61 | 1.79 | 0.84 | 1.76 | 0.76 | 0.70 |
| 6–11 years | 2.07 | 1.39 | 0.81 | 1.90 | 1.10 | 1.00 | 0.61 | 0.17 | 0.42 |
| ≥12 years | 2.07 | 1.39 | 0.81 | 1.90 | 1.10 | 1.00 | 0.61 | 0.17 | 0.42 |

Gender

| Male | Ref. | 0.69 | 0.26 | 0.87 | 0.39 | 0.43 | 0.20 | 0.91 | 0.08 |
| Female | 0.82 | 0.73 | 0.91 | 0.85 | 0.77 | 0.92 | 0.90 | 0.84 | 0.97 |

Weight (kg)

| Yes | 15.84 | 5.38 | 46.62 | 12.29 | 5.14 | 29.36 | 5.63 | 2.67 | 11.85 | 0.49 | 0.19 | 1.25 | 1.28 | 0.31 | 5.31 |
| No | 1.06 | 8.98 | 4.29 | 2.79 | 1.01 | 7.75 | 1.79 | 0.77 | 4.18 | 1.78 | 0.76 | 4.16 | 1.21 | 1.10 | 8.58 | 1.04 | 2.22 | 4.94 |

Comorbidities

| Yes | 3.08 | 1.06 | 8.98 | 4.29 | 2.79 | 1.01 | 7.75 | 1.79 | 0.77 | 4.18 | 1.78 | 0.76 | 4.16 | 1.21 | 1.10 | 8.58 | 1.04 | 2.22 | 4.94 |

Chest X-ray

| Yes | 1.77 | 0.67 | 4.70 | 2.59 | 1.13 | 5.91 | 1.96 | 0.94 | 4.08 | 1.04 | 0.48 | 2.24 | 0.35 | 0.04 | 3.14 | 1.01 | 0.24 | 4.23 |

Fever

| Yes | 0.63 | 0.24 | 1.70 | 1.43 | 0.56 | 3.69 | 0.67 | 0.32 | 1.40 | 2.96 | 1.08 | 8.10 | 0.15 | 0.03 | 0.89 | 1.64 | 0.33 | 8.24 |

Bold font indicated significant p<0.05
*Adjusted regression models for age
LDH, lactate dehydrogenase; Ref., reference.
we found that dyspnoea, abnormal chest radiographic findings, lethargy, elevated initial ferritin and elevated D-dimer were significantly associated with the development of complications in our cohort. Lymphocytopenia and increased LDH differed significance among age groups. This observation has been reported before.35 36 The presence of dyspnoea, leucocytosis, abnormal chest radiographic findings and comorbidities at the time of presentation was significantly associated with an increased risk for ICU admission among our cohort. In comparison, AAántunéz-Montes et al reported a relatively similar observation through their Multinational Latin American study involving a cohort of four hundred nine children. Preexisting medical condition, immunodeficiency, lower respiratory tract infection, gastrointestinal symptoms, abnormal radiologic changes and low socioeconomic conditions were their reported risk factors for admission to the ICU.37

Our reported fatality rate (0.5%) is consistent with the previously reported percentage (<2%) in other international paediatric COVID-19 studies.10 38–40 In the UK, The International Severe Acute Respiratory and Emerging Infection Consortium study reported a fatality rate of 0.9% due to Paediatric COVID-19.41 In another recent English study, the fatality rate in children who died of SARS-CoV-2 was 0.2 per 100,000 person years (95% Poisson CI) compared with 25.5 per 100,000 for all other causes of death.42 In the USA, fatality rate of paediatric COVID-19 reached 0.9%.43 In our cohort, 99.49% patients were discharged without a negative prognosis.

Our interventional management options included the use of non-invasive ventilation, mechanical ventilation, administration of dexamethasone, hydroxychloroquine, antiviral agents or a combination of two or more of these options. Most of our cohort received supportive treatment; however, few (3.6%) received hydroxychloroquine,
dexamethasone or a combination of both. The sole reliance on supportive treatment for managing paediatric COVID-19, regardless of its severity, is well reported in the literature. Most children requiring more than supportive management, that is, interventional management, were school-aged children (aged 6–11 years) and children with comorbid diseases. Data on the appropriate pharmacological choices for COVID-19 treatment are still under study by various institutions, and the proposed guidelines are not generalised yet for the paediatric population. Cao et al recommended following their randomised, controlled, open-label trial for hospitalised adult patients with confirmed SARS-CoV-2 infection, stating that antiviral drugs should be reserved for patients with severe disease. Furthermore, the WHO Guideline Development Group for COVID-19 drug treatments strongly recommended the use of systemic corticosteroids to treat patients with severe and critical COVID-19.

Our study has some limitations, including its retrospective design that could affect the quality of such a study. Furthermore, we could not formulate a conclusion on the long-term effects of COVID-19 on the paediatric population as our follow-up period ended at discharge. One of the major strengths of our study is being one of the largest multicentre studies that followed up paediatric patients during their hospital admission.

CONCLUSION
COVID-19 presentation in the paediatric population ranges from mild to severe disease, depending on the age group. However, most of our participants presented with mild or asymptomatic COVID-19. Furthermore, the presence of dyspnoea, abnormal chest radiographic findings, lethargy, elevated ferritin, and elevated D-dimer were associated with the development of complications among our participants. The presence of dyspnoea, leucocytosis, abnormal chest radiographic findings and comorbidities at the time of presentation was associated with an increased probability of ICU admission.

Author affiliations
1Department of Pediatrics, Imam Abdulrahman Bin Faisal University, King Fahd Hospital of the University, AlKhobar, Saudi Arabia
2College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
3Department of Family and Community Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
4Department of Pediatrics, Umm Al-Qura University, Makkah, Saudi Arabia
5Department of Pediatrics, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
6Department of Pediatrics, John Hopkins Aramco Healthcare, Dhahran, Saudi Arabia
7Pediatric Pulmonology and Sleep Medicine Department, King Saud Medical City, Riyadh, Saudi Arabia
8Department of Pediatrics, Imam Abdulrahman Bin Faisal University College of Medicine, Dammam, Saudi Arabia

Correction notice This article has been corrected since it was first published.

Twitter Faisal O AlQurashi @Faisal_OQurashi

Contributors WHA, AAY, MHA-Q, DKB and AAL conceptualised and designed the study, WHA and AAA designed the data collection instrument, AAY, AHA, SIAM and AA coordinated and supervised data collection. ASA, SAK, NIH, WAA, AHA, HWA and BJA collected data. AAA carried out the initial analyses, FOA, BJA and AHA drafted the initial manuscript. AAL, SAA-T, AAY, AHA, SIAM, AA, MHA-Q and HWA reviewed and revised the manuscript. WHA is the guarantor of the study. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The Institutional Review Board (IRB) of Imam Abdulrahman Bin Faisal University approved this study (IRB-2020-01-281). The IRB waived the need for obtaining informed consent because of the retrospective nature of the study. Furthermore, data confidentiality was ensured following the Declaration of Helsinki principles.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The data that support the findings of this study are available from the corresponding author, FOA, on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Faisal O AlQurashi http://orcid.org/0000-0003-3411-819X

REFERENCES
1 World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19, 2020. Available: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-3-march-2020 [Accessed 15 Oct 2020].
2 CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422–6.
3 Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr 2020;16:223–31.
4 Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514–23.
5 Wei M, Yuan J, Liu Y, et al. Novel coronavirus infection in hospitalized infants under 1 year of age in China. JAMA 2020;323:1313–4.
6 Rasmussen SA, Thompson LA. Coronavirus disease 2019 and children: what pediatric health care clinicians need to know. JAMA Pediatr 2020;174:743–4.
7 Vos ERA, den Hartog G, Scheppe RM, et al. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave. J Epidemiol Community Health 2020;0:1–7.
8 Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020;323:1335.
9 Tagarro A, Epaleta C, Santos M. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr 2020, [Epub ahead of print: 08 Apr 2020]. doi:10.1001/jamapediatrics.2020.1346.
10 Götzinger F, Santiago-Garrido B, Noguera-Julían A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020;4:653–61.
11 Alsofayyan YM, Althunayyan SM, Khan AA, et al. Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study. J Infect Public Health 2020;13:920–5.
12 Al-Omari A, Alhurbani WN, Zaidi ARZ, et al. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia:
Xia W, et al. Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: an ecological study. 2020;8:506.

Kari JA, Shalaby MA, Albanna AS, et al. Coronavirus disease in children: a multi-centric study from the Kingdom of Saudi Arabia. J Infect Public Health 2021;14:543–9.

Alnajjar AA, Dohain AM, Abdelmohsen GA, et al. Clinical characteristics and outcomes of children with COVID-19 in Saudi Arabia. Saudi Med J 2021;42:391–8.

COVID-19 coronavirus disease guidelines, 2020. Available: https://covid19.cdc.gov/sa/wp-content/uploads/2020/10/EN_COVID_19_Coronavirus_Disease_Guidelines_v2.0.pdf.

Al-Tawfiq JA, Memish ZA, COVID-19 in the eastern Mediterranean region and Saudi Arabia: prevention and therapeutic strategies. Int J Antimicrob Agents 2020;55:105968.

Kollmann TR, Kampmann B, Mazmanian SK, et al. Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. Immunity 2017;46:350–63.

Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatr. 2020;145:e20200702.

Ding Y, Yan H, Guo W. Clinical characteristics of children with COVID-19: a meta-analysis. Front Pediatr 2020;8:431.

Kanthimathinathan HK, Dhesi A, Hartshorn S, et al. COVID-19: a UK children’s Hospital experience. Hosp Pediatr 2020;10:802–5.

Chang T-H, Wu J-L, Chang L-Y. Clinical characteristics and diagnostic challenges of pediatric COVID-19: a systematic review and meta-analysis. J Formos Med Assoc 2020;119:982–9.

Mantovani A, Rinaldi E, Zusi C, et al. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis. Pediatr Res 2021;89:733–7.

Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol 2020;55:1169–74.

World Health Organization. Laboratory testing strategy recommendation for COVID19: interim guidance. Available: https://www.who.int/publications/i/item/laboratory-testingstrategy-recommendations-for-covid-19-interim-guidance [Accessed 15 Mar 2021].

El-Kafrawy SA, El-Daly MM, Hassan AM, et al. A direct method for RT-PCR detection of SARS-CoV-2 in clinical samples. Healthcare 2021;9:37.

Liguore I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in children and adolescents: a systematic review. Eur J Pediatr 2020;179:1029–46.

Yu Y, Chen P. Coronavirus disease 2019 (COVID-19) in neonates and children from China: a review. Front Pediatr 2020;8:287.

Hon KLE, Leung CW, Cheng WFT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003;361:1701.

Cheng FWT, Ng PC, Chiu WK, et al. A case-control study of SARS versus community acquired pneumonia. Arch Dis Child 2005;90:747–9.

Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, et al. COVID-19 and multisystem inflammatory syndrome in Latin American children: a multination study. Pediatr Infect Dis J 2021;40:e1–6.

Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA Pediatr 2020;174:e202430.

Cura Yayla BC, Özsürekçi Y, Aykaç K. Characteristics and management of children with COVID-19 in turkey. Balk Med J 2020;37:341–7.

Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663–5.

Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020;370:m3249.

Smith C, Odd D, Harwood R, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first UK pandemic year. Nat Med 2020;26:185–92.

Kompanijets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021;4:e2111182.

Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter initial guidance on use of antivirals for children with coronavirus disease 2019/Severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc 2020;9:701–15.

Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases Society of America guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis 2020;382.

Larson DT, Bhattacharya S, St Super K, Greenson R, et al. The response of the pediatric intensive care unit to the 2019 novel coronavirus pandemic: a case series. Pediatrics 2020;146(3). E20672020.

World Health Organization. Corticosteroids for COVID-19: living guidance, 2020. Available: https://apps.who.int/iris/handle/10665/334125